The impact of HER2-directed targeted therapy on HER2-positive DCIS of the breast

BACKGROUND: In invasive breast cancer, HER2 is a well-established negative prognostic factor. However, its significance on the prognosis of ductal carcinoma in situ (DCIS) of the breast is unclear. As a result, the impact of HER2-directed therapy on HER2-positive DCIS is unknown and is currently the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Gary. D., Haque, Waqar, Farach, Andrew, Hatch, Sandra S., Butler, E. Brian, Niravath, Polly A., Schwartz, Mary R., Bonefas, Elizabeth, Teh, Bin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241310/
https://www.ncbi.nlm.nih.gov/pubmed/34211767
http://dx.doi.org/10.5603/RPOR.a2021.0026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241310/
https://www.ncbi.nlm.nih.gov/pubmed/34211767
http://dx.doi.org/10.5603/RPOR.a2021.0026

Ejemplares similares